



21 Firstfield Road  
Gaithersburg, MD 20878  
T 240-268-2000  
F 240-268-2100

www.novavax.com  
Nasdaq: NVAX

**NOVAVAX Letter to PREVENT-19 Trial Participants**  
**July 30, 2021**

To all participants in our PREVENT-19 clinical trial,

First, from everyone at Novavax, I want to extend our sincerest thanks for participating in our NVX-CoV2373 clinical trial. Participation in clinical trials is a crucial part of medical research. We appreciate your contribution to public health and your dedication to the advancement of a COVID-19 vaccine candidate, and firmly believe that clinical trial participants should not be disadvantaged with respect to providing proof of vaccination.

We are glad that you were able to receive a vaccine earlier than most. We also empathize with you as we recognize that proof of vaccination may be necessary to travel to certain destinations and for engaging in some post-restriction activities. As a PREVENT-19 trial participant who received active vaccine, you are now eligible to receive a modified vaccination card provided by the Centers for Disease Control and Prevention (CDC). This card will serve as documentation of your participation in the study, and that you have been vaccinated against COVID-19.

The modified vaccination cards are now being proactively distributed to trial participants by ICON, our contract research organization, in coordination with the trial sites. The card states that you have been vaccinated through a clinical trial and are to be considered fully vaccinated for public health purposes. Should NVX-CoV2373 receive regulatory authorization, you may also receive the standard CDC vaccination card if desired, and the vaccine can be recorded in the Immunization Information Systems (IIS). Please reach out to your trial site if you do not receive this card or if you have questions.

The COVID-19 pandemic has been unprecedented and required vaccine development in record time. While the vaccine development and manufacturing process is complex, we are working around the clock to complete our regulatory filing as quickly as possible. Until then, NVX-CoV2373 continues to demonstrate strong safety and efficacy in ongoing clinical trials.

Thank you again for your participation in the Novavax study.

Sincerely,

Stanley C. Erck, CEO and President of Novavax